ESRRB and cancer: While expression of NR2F6 (an orphan nuclear receptor) has been linked to malignant growth and progression in multiple cancer types, in tumor-reactive T cells, NR2F6 functions to repress expression of effector cytokines and acts as an intracellular immune checkpoint that inhibits CD8+ T cell infiltration and suppresses anti-tumor immune responses (35).